Login Register Cart 0
Generic placeholder image

Current Molecular Medicine

Editor-in-Chief

ISSN (Print): 1566-5240
ISSN (Online): 1875-5666

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe Translate in Chinese
Research Article

Interferon Signature’s Members, a Novel Altered Correlation upon Interferon-β Treatment in Multiple Sclerosis Patients

Author(s): Sarvin Jabbari, Mohammadali Hosseinpourfeizi, Reza Safaralizadeh* and Behzad Baradaran*

Volume 24, Issue 10, 2024

Published on: 12 October, 2023

Page: [1301 - 1306] Pages: 6

DOI: 10.2174/0115665240251182231008040710

Price: $65

Open Access Journals Promotions 2
conference banner
Abstract

Background: Multiple sclerosis (MS) is a chronic inflammatory disease that affects the central nervous system and is characterized by extensive brain damage and neurodegeneration. Immunological, genetic, and histological analyses of MS patients provide data in support of the concept that autoimmunity plays a crucial role in the condition's course. It has been proposed that MS may be treated with interferon (IFN)-β and other members of the type I family.

Objective: Low levels of type I IFN in MS patients may affect immunological control, establish the threshold for an IFN therapeutic response, and be "primed" or "fixed" by IFN therapy.

Methods: This study was conducted as a cross-sectional study. qRT-PCR was used to examine the expression of two critical IFN regulatory genes, IFI44 and MX1, in MS patients receiving IFN-β treatment.

Results: The findings demonstrated a considerable rise in the expression of both genes in MS patients treated with IFN-β compared to those newly diagnosed with the illness. In addition, IFI44 and MX1 might be positively associated with their expression after IFN-β therapy and be regarded as IFN-β responsiveness indicators.

Conclusion: The IFI44/MX1 axis could act as one of the crucial regulators of the disease following IFN-β treatment.

Keywords: Interferon-β therapy, interferon regulatory genes, interferon signature, IFI44, MX1, multiple sclerosis.

« Previous Next »
[1]
Lassmann H, Brück W, Lucchinetti CF. The immunopathology of multiple sclerosis: An overview. Brain Pathol 2007; 17(2): 210-8.
[http://dx.doi.org/10.1111/j.1750-3639.2007.00064.x] [PMID: 17388952]
[2]
Correale J, Gaitán MI, Ysrraelit MC, Fiol MP. Progressive multiple sclerosis: From pathogenic mechanisms to treatment. Brain 2017; 140(3): 527-46.
[PMID: 27794524]
[3]
Compston A, Coles A. Multiple sclerosis. Lancet 2008; 372(9648): 1502-17.
[http://dx.doi.org/10.1016/S0140-6736(08)61620-7] [PMID: 18970977]
[4]
McFarland HF, Martin R. Multiple sclerosis: A complicated picture of autoimmunity. Nat Immunol 2007; 8(9): 913-9.
[http://dx.doi.org/10.1038/ni1507] [PMID: 17712344]
[5]
Langrish CL, Chen Y, Blumenschein WM, et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 2005; 201(2): 233-40.
[http://dx.doi.org/10.1084/jem.20041257] [PMID: 15657292]
[6]
Steinman L. A brief history of TH17, the first major revision in the TH1/TH2 hypothesis of T cell-mediated tissue damage. Nat Med 2007; 13(2): 139-45.
[http://dx.doi.org/10.1038/nm1551] [PMID: 17290272]
[7]
Dargahi N, Katsara M, Tselios T, et al. Multiple sclerosis: Immunopathology and treatment update. Brain Sci 2017; 7(12): 78.
[http://dx.doi.org/10.3390/brainsci7070078] [PMID: 28686222]
[8]
Jakimovski D, Kolb C, Ramanathan M, Zivadinov R, Weinstock-Guttman B. Interferon β for multiple sclerosis. Cold Spring Harb Perspect Med 2018; 8(11): a032003.
[http://dx.doi.org/10.1101/cshperspect.a032003] [PMID: 29311124]
[9]
Feng X, Bao R, Li L, Deisenhammer F, Arnason BGW, Reder AT. Interferon-β corrects massive gene dysregulation in multiple sclerosis: Short-term and long-term effects on immune regulation and neuroprotection. EBioMedicine 2019; 49: 269-83.
[http://dx.doi.org/10.1016/j.ebiom.2019.09.059] [PMID: 31648992]
[10]
Pan H, Wang X, Huang W, et al. Interferon-induced protein 44 correlated with immune infiltration serves as a potential prognostic indicator in head and neck squamous cell carcinoma. Front Oncol 2020; 10: 557157.
[http://dx.doi.org/10.3389/fonc.2020.557157] [PMID: 33123469]
[11]
Feng X, Wu H, Grossman JM, et al. Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus. Arthritis Rheum 2006; 54(9): 2951-62.
[http://dx.doi.org/10.1002/art.22044] [PMID: 16947629]
[12]
Hooks JJ, Moutsopoulos HM, Geis SA, Stahl NI, Decker JL, Notkins AL. Immune interferon in the circulation of patients with autoimmune disease. N Engl J Med 1979; 301(1): 5-8.
[http://dx.doi.org/10.1056/NEJM197907053010102] [PMID: 449915]
[13]
Ohl K, Tenbrock K. Inflammatory cytokines in systemic lupus erythematosus. J Biomed Biotechnol 2011; 2011: 1-14.
[http://dx.doi.org/10.1155/2011/432595] [PMID: 22028588]
[14]
Ontaneda D, Thompson AJ, Fox RJ, Cohen JA. Progressive multiple sclerosis: Prospects for disease therapy, repair, and restoration of function. Lancet 2017; 389(10076): 1357-66.
[http://dx.doi.org/10.1016/S0140-6736(16)31320-4] [PMID: 27889191]
[15]
Reder AT, Velichko S, Yamaguchi KD, et al. IFN-β1b induces transient and variable gene expression in relapsing-remitting multiple sclerosis patients independent of neutralizing antibodies or changes in IFN receptor RNA expression. J Interferon Cytokine Res 2008; 28(5): 317-31.
[http://dx.doi.org/10.1089/jir.2007.0131] [PMID: 18547162]
[16]
DeDiego ML, Nogales A, Martinez-Sobrido L, Topham DJ. Interferon-induced protein 44 interacts with cellular FK506-binding protein 5, negatively regulates host antiviral responses, and supports virus replication. MBio 2019; 10(4): e01839-19.
[http://dx.doi.org/10.1128/mBio.01839-19] [PMID: 31455651]
[17]
Hallen LC, Burki Y, Ebeling M, et al. Antiproliferative activity of the human IFN-α-inducible protein IFI44. J Interferon Cytokine Res 2007; 27(8): 675-80.
[http://dx.doi.org/10.1089/jir.2007.0021] [PMID: 17784819]
[18]
Wang H, Lu B, Ren S, et al. Long noncoding RNA LINC01116 contributes to gefitinib resistance in non-small cell lung cancer through regulating IFI44. Mol Ther Nucleic Acids 2020; 19: 218-27.
[http://dx.doi.org/10.1016/j.omtn.2019.10.039] [PMID: 31841994]
[19]
Xu H, Chen J, Wang Y, Wu Y, Liang Y. SELL and IFI44 as potential biomarkers of Sjögren’s syndrome and their correlation with immune cell infiltration. Genes Genet Syst 2021; 96(2): 71-80.
[http://dx.doi.org/10.1266/ggs.20-00053] [PMID: 33883324]
[20]
Fattahi M, Rezaei N, Nematalahi FS, et al. MicroRNA-29b variants and MxA expression change during interferon beta therapy in patients with relapsing-remitting multiple sclerosis. Mult Scler Relat Disord 2019; 35: 241-5.
[http://dx.doi.org/10.1016/j.msard.2019.07.034] [PMID: 31421628]
[21]
Libertinova J, Meluzinova E, Matoska V, et al. MxA mRNA decrease preceding NAb detection in IFNβ-treated MS patients. Brain Behav 2017; 7(3): e00644.
[http://dx.doi.org/10.1002/brb3.644] [PMID: 28293479]
[22]
Matas E, Bau L, Martínez-Iniesta M, Romero-Pinel L, Mañé-Martínez MA, Martínez-Yélamos S. Absence of MxA induction is related to a poor clinical response to interferon beta treatment in multiple sclerosis patients. J Neurol 2016; 263(4): 722-9.
[http://dx.doi.org/10.1007/s00415-016-8053-z] [PMID: 26872667]

Rights & Permissions Print Cite
Article Metrics
16
1
Wayfinder Image
Open Access Journals Promotions
© 2024 Bentham Science Publishers | Privacy Policy